Chongqing Kangning Bio. v. Conrex Pharmaceutical

2024 Pa. Super. 255, 327 A.3d 209
CourtSuperior Court of Pennsylvania
DecidedNovember 1, 2024
Docket2747 EDA 2023
StatusPublished
Cited by3 cases

This text of 2024 Pa. Super. 255 (Chongqing Kangning Bio. v. Conrex Pharmaceutical) is published on Counsel Stack Legal Research, covering Superior Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Chongqing Kangning Bio. v. Conrex Pharmaceutical, 2024 Pa. Super. 255, 327 A.3d 209 (Pa. Ct. App. 2024).

Opinion

J-A21002-24

2024 PA Super 255

CHONGQING KANGNING : IN THE SUPERIOR COURT OF BIOENGINEERING CO., LTD, A : PENNSYLVANIA DEREGISTERED CHINESE COMPANY : : v. : : CONREX PHARMACEUTICAL CORP. : : APPEAL OF: : : CHONGQING KANGNING : BIOENGINEERING CO., LTD AND ITS : SHAREHOLDERS AND PURPORTED : SUCCESSORS IN INTEREST, ZOU : XIAOPNG AND ZHOU BANGLI : No. 2747 EDA 2023

Appeal from the Order Entered September 22, 2023 In the Court of Common Pleas of Chester County Civil Division at No(s): 2019-08925-CT

BEFORE: KUNSELMAN, J., NICHOLS, J., and BECK, J.

OPINION BY KUNSELMAN, J.: FILED NOVEMBER 1, 2024

I. Introduction

In this international-commerce case, the Plaintiff, Chongqing Kangning

Bioengineering Co., Ltd. (“CKB”), and its Shareholders, Zou Xiaopng and Zhou

Bangli, appeal from the order dismissing CKB’s complaint against Conrex

Pharmaceutical Corp. Following a bench trial, the Court of Common Pleas of

Chester County ruled that it lost subject-matter jurisdiction after CKB

deregistered under Chinese law.1 Because deregistration (or dissolution) of a

____________________________________________

1 CKB was a Chinese company. The parties agree that deregistration under Chinese law is the equivalent of business dissolution under Pennsylvania law. J-A21002-24

business entity has no bearing on subject-matter jurisdiction, we reverse and

remand for further proceedings.

II. Factual & Procedural Background

In 2019, CKB sued Conrex Pharmaceutical Corp., a Pennsylvania

corporation, in Chester County. CKB brought counts for breach of contract,

unjust enrichment, conversion, and account stated.

Conrex filed various counterclaims, and CKB preliminarily objected. The

trial court ruled in favor of Conrex, and CKB appealed. Reversing, this Court

dismissed Conrex’s counterclaims, because they were subject to arbitration.

See Chongqing Kangning Bioengineering Co., Ltd. v. Conrex Pharm.

Corp., 253 A.3d 293 (Pa. Super. 2021) (non-precedential decision).

On November 5, 2021, the trial court, sua sponte, stayed this case to

allow Conrex an opportunity to arbitrate its counterclaims. Conrex elected not

do so. Three months later, on February 1, 2022, CKB deregistered under

Chinese law. Then, in March of 2023, CKB moved to end the stay. The trial

court lifted the stay and scheduled a bench trial for July 18, 2023.

According to CKB’s counsel, he first learned of his client’s deregistration

a few days prior to trial. He informed Conrex’s attorney and the trial court

before the trial began. At the close of evidence, the court made no decision.

Instead, it issued a rule to show cause directing CKB to demonstrate why

Conrex “was not entitled to the relief requested.” T.C.O., 7/21/23, at 1. The

trial court explained its show-cause order in the following footnote:

-2- J-A21002-24

An examination of the Complaint and Answer reveals that [Conrex] has denied the averments set forth in paragraphs 3 and 4 of the Complaint[2] and constitutes a challenge to [the trial court’s] jurisdiction. See Drake Manufacturing Co. v. Polyflow, Inc., 109 A.3d 250 (Pa. Super. 2015). The parties will specifically address the jurisdiction of the trial court to proceed in this matter. Specifically, whether [CKB] is registered to do business in Pennsylvania pursuant to 15 Pa.C.S.A. §411 (in light of the numerous transactions between the parties in Pennsylvania, [CKB] acquiring [Conrex’s] trademark, and [CKB] seeking [Conrex’s] assistance in establishing operations in the United States and Canada.) See 15 Pa.C.S.A. §401, et seq.; 403; 411; 417 (status of foreign dissolution).

Id. at 1, n.2.

CKB filed a response and included a footnote to amend the complaint to

substitute CKB’s Shareholders as the plaintiffs. “As identified herein, to the

extent necessary, [CKB] moves to amend its Complaint to identify Zou

Xiaopng and Zhou Bangli as its successors/the Plaintiffs in this proceeding.”

Response to Trial Court’s Rule to Show Cause at 1, n.1.

In addition, CKB indicated that Conrex never raised the issue of CKB’s

supposed lack of capacity to sue under Drake Manufacturing, supra, and

therefore waived the issue raised in the show-cause order. Furthermore, CKB

differentiated the question of subject-matter jurisdiction from the question of

2 Paragraphs three and four of the complaint were boilerplate allegations. “3. Jurisdiction is proper in this court pursuant to 42 Pa. C.S. §§ 931, 5301. 4. Chester County is the proper venue because the transaction from which this dispute arises took place in this county, and [Conrex] regularly conducts business in this county.” Complaint at 2. In response, Conrex pleaded, “3-4. The averments of the corresponding paragraphs consist of one or more conclusions of law and, as such, are deemed denied.” Answer at 2. Conrex did not file preliminary objections challenging either jurisdiction or venue.

-3- J-A21002-24

capacity to sue. It demonstrated that its causes of actions fell within the trial

court’s subject-matter jurisdiction, because they belonged to the class of

cases that the trial court was competent to adjudicate. Lastly, CKB provided

a “Foreign Law Opinion” from Yang Song, a Chinese attorney. Mr. Yang

explained that, in his view, a deregistered Chinese company may continue

actions to collect debts owed to it, via its former shareholders, acting as the

real parties in interest.

Conrex answered that it contested subject-matter jurisdiction from the

start of the lawsuit, because “this matter belongs in international arbitration

in accordance with the parties’ Collaboration Agreement . . . .” Conrex’s Reply

to CKB’s Response to Trial Court’s Order to Show Cause at 1. Conrex also

claimed that CKB was no longer authorized to do business in its own country,

let alone anywhere else. Because 15 Pa.C.S.A § 411 requires foreign

corporations to be registered with the Secretary of State of Pennsylvania to

sue in this Commonwealth, Conrex agreed with the trial court’s suggestion

that CKB could not pursue this action after it deregistered in China.

Regarding the motion to substitute Mr. Zou and Mr. Zhou as named-

plaintiffs for CKB, Conrex argued that the Shareholders were strangers to the

action who did not appear or verify any pleadings. It also claimed there was

no evidence at trial proving CKB’s ownership structure. Hence, in Conrex’s

view, Mr. Zou and Mr. Zhou could not show that they had standing to

substitute for CKB.

-4- J-A21002-24

The trial court heard oral argument on September 18, 2023. Three days

later, the court entered an order entitled “DECISION,” which it said was issued

“pursuant to [its] Rule issued July 21, 2023,” and dismissed CKB’s lawsuit “for

failure to join an indispensable party.” T.C.O., 9/22/23, at 1. The show-cause

order never mentioned the issue of nonjoinder of indispensable parties, nor

did the trial court explicitly say who those supposedly indispensable parties

were. Seemingly, the court meant the Shareholders whom CKB moved to

substitute in response to the rule to show cause. The trial court found that

the Shareholders presented insufficient evidence to substitute themselves for

CKB.

CKB, Mr. Zou, and Mr. Zhou (collectively “Appellants”) jointly appealed

from the order.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Plunkett, C. v. Alpha Power Sports
Superior Court of Pennsylvania, 2026
JM Enterprises v. Zuber, D.
Superior Court of Pennsylvania, 2026
T. Harris v. PA DOC
Commonwealth Court of Pennsylvania, 2026
Com. v. Schmidt, L.
Superior Court of Pennsylvania, 2025
H&M Holdings v. Patrono
Superior Court of Pennsylvania, 2025

Cite This Page — Counsel Stack

Bluebook (online)
2024 Pa. Super. 255, 327 A.3d 209, Counsel Stack Legal Research, https://law.counselstack.com/opinion/chongqing-kangning-bio-v-conrex-pharmaceutical-pasuperct-2024.